The Quality Brief
Every new FDA drug and device warning letter and recall, summarized once a week. Free. Subscribe, then read this week's issue below.
This week's issue
The most recent FDA drug and device enforcement activity.
Warning letters (15)
Apr 14, 2026
Drug establishment
CGMP/Finished Pharmaceuticals/Adulterated/Unapproved New Drug
Apr 14, 2026
Drug establishment
Notice of Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet
Apr 14, 2026
Drug establishment
Finished Pharmaceuticals/Unapproved New Drug/Misbranded/Adulterated
Apr 14, 2026
Drug establishment
Notice of Unlawful Sale of Unapproved Drugs to United States Consumers Over the Internet
Apr 14, 2026
Drug establishment
Notice of Unlawful Sale of Unapproved Drugs to United States Consumers Over the Internet
Apr 14, 2026
Drug establishment
Notice of Unlawful Sale of Unapproved Drugs to United States Consumers Over the Internet
Apr 14, 2026
Drug establishment
CGMP/Finished Pharmaceuticals/Adulterated/Unapproved New Drug
Apr 9, 2026
Drug establishment
Drug Supply Chain Security Act (DSCSA) Violations
Apr 7, 2026
Drug establishment
Unapproved New Drugs Sold Over the Internet
Apr 7, 2026
Drug establishment
Unapproved New Drugs Sold Over the Internet
Recalls (0)
None in this period.
Warning letters from the FDA warning-letter database; recalls from openFDA enforcement reports. Drug and device only. Each firm links to its FacilityLedger profile where we have one, otherwise to the FDA record.